Generalised cost-effectiveness analysis for breast cancer prevention and care in Hong Kong Chinese
IOL Wong, JWH Tsang, BJ Cowling, GM Leung
School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong
Key Messages
1. A state-transition Markov model was used to evaluate various interventions across different breast cancer stages based on the generalised cost-effectiveness analysis.
2. From all strategies considered, the optimal allocation of additional resources for breast cancer in descending order would be: 25% reduction in waiting time for postoperative radiotherapy (average cost-effectiveness ratio, US$5000 per quality-adjusted life year [QALY]); enhanced, home-based palliative care (US$7105 per QALY); adjuvant, sequential endocrine therapy (US$17 963 per QALY); targeted immunotherapy (US$62 092 per QALY); and mass mammography screening for women aged 40 to 69 years (US$72 576 per QALY).
3. The generalised cost-effectiveness analysis for the full range of interventions for the same disease enables rational prioritisation and coherent allocation of resources.